Recent Updates
Recently added Catalysts

Lisaftoclax

Phase 3

Higher-risk Myelodysplastic Syndrome | Small molecule | Hematology |Ascentage Pharma Group International - American Depository Shares|Last Updated: Nov 20, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment490
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06641414Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).PHASE3 RECRUITING 490 — — Jan 22, 2025Dec 1, 2029Nov 20, 20252 United States, China
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
PurposeTREATMENT
Interventions
NameTypeDescription
Lisaftoclax (APG-2575)DRUGQD, oral administration.
Azacitidine InjectionDRUGQD, hypodermic or intravenous injection.
PlaceboOTHERQD, oral administration.
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06641414studyFirstPostDate: changed